Answers are grounded in this paper and cite their sources.
Macrophage activation plays a pivotal role in tumor progression, immune regulation, and therapeutic responsiveness. However, the impact of macrophage activation-related genes (MARGs) on tumor immune heterogeneity and clinical outcomes in lung adenocarcinoma (LUAD) remains incompletely understood. This study aimed to develop and evaluate a macrophage activation-related prognostic signature and explore its clinical and biological significance in LUAD. Bulk RNA sequencing data and clinical information from TCGA-LUAD and multiple GEO cohorts were integrated to identify prognostic MARGs. A machine learning framework comprising 64 combinations derived from 10 algorithms was employed to construct the optimal prognostic model. Immune landscape characteristics, immunotherapy responsiveness, and drug sensitivity were systematically evaluated between risk groups. Single-cell RNA sequencing data were analyzed to investigate tumor microenvironment heterogeneity and cell type-specific gene expression patterns. Furthermore, RT–qPCR, immunohistochemistry, and in vitro functional assays were performed to validate the expression and biological function of key prognostic genes. A macrophage activation-related gene signature (MARG signature) consisting of nine genes ( ADH4 , AGXT , CHIA , CTCFL , F2 , FGA , HOXD11 , SLCO1B1 , and UPK1B ) was established using the RSF + plsRcox model, which achieved the highest average C-index among 64 machine learning combinations. Patients in the High-Risk group exhibited significantly poorer overall survival than did those in the Low-Risk group. The prognostic model achieved AUC values of 0.638, 0.651, and 0.598 for predicting 1-, 3-, and 5-year overall survival, respectively. The MARG signature risk score was identified as an independent prognostic factor and was significantly associated with immune cell infiltration, immunogenic cell death-related gene expression, immune checkpoint expression, and predicted immunotherapy response, with exploratory analyses also revealing associations with predicted drug sensitivity. Single-cell analysis revealed substantial tumor microenvironment heterogeneity and distinct cell type-specific expression patterns of key prognostic genes. Experimental validation confirmed the dysregulated expression of multiple signature genes in LUAD tissues. Notably, ADH4 was significantly downregulated in LUAD. Functional assays revealed that ADH4 overexpression suppressed LUAD cell proliferation and migration while potentially promoting an M1-like phenotypic shift in cocultured THP-1-derived macrophages. We developed and evaluated a machine learning-derived MARG signature for prognostic prediction and therapeutic evaluation in LUAD. Our findings highlight the potential value of macrophage activation in shaping tumor immune heterogeneity and identify ADH4 as a potential tumor suppressor associated with LUAD progression. Not applicable.
No takes yet. Share an insight, caveat, or question.
Lan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: